| CASE REPORT |
|
| Year : 2022 | Volume
: 26
| Issue : 2 | Page : 92-95 |
|
|
Topical immunotherapy for alopecia areata: A successful diphenylcyclopropenone protocol
Melika Motamedi1, Kush Bapujib2, Navdeep Dhaliwal1
1 Department of Medicine, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
2 Department of Sciences, Faculty of Sciences, University of Alberta, Edmonton, Alberta, Canada
Correspondence Address:
Dr. Navdeep Dhaliwal
University of Alberta, 116 Street and 85 Avenue, Edmonton T6G 2R3, Alberta
Canada
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jdds.jdds_21_22
|
|
|
Alopecia areata (AA) is an autoimmune disorder that involves the destruction of anagenic hair follicles, resulting in non-scarring patchy hair loss. The patient presented in the following case had not seen improvement by use of conventional treatments and was started on topical immunotherapy, diphenylcyclopropenone (DPCP). This agent is commonly left as a last resort due to its constant need for follow-up, clinician-required administration, and risk of adverse effects. The following case presents a titration schedule using DPCP, resulting in minimal adverse effects and dramatic improvement in hair regeneration.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
